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EBV infection in AIDS-DLBCL is consistently linked to plasmacytoid/
plasmablastic differentiation.4
Although latency programs predominate in EBV-driven tumors,
lytic EBV replication may also be of pathogenic relevance, at least in
the early phases of cell transformation.5,6 This ﬁnding is particularly
relevant for AIDS-related lymphomagenesis, since the underlying
impairment of immune responses may favor uncontrolled activation
of EBV lytic replication in latently infected B lymphocytes. Im-
portantly, regarding tumor microenvironment, EBV infection is impli-
cated in angiogenic mechanisms.5-7 In conclusion, the results reported
by Liapis and colleagues1 are consistent with genetic and virological
data suggesting that in AIDS-DLBCL, neovascularization is linked to
EBV status of tumor and to immunoblastic features.
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To the editor:
No familial aggregation in chronic myeloid leukemia
There is a ﬁvefold to sevenfold elevated risk of myeloproliferative
neoplasms (MPNs) among ﬁrst-degree relatives of MPN patients.1,2
In contrast, aside from early-onset patients, there is no signiﬁcant
familial aggregation in acute myeloid leukemia (AML).3
The molecular underpinnings of the development of chronic
myeloid leukemia (CML) are unclear. Ionizing radiation in high
doses is the only known risk factor.4 Benzene and benzene-containing
products have been reported to be signiﬁcantly related to morbidity
and mortality from CML,5 although recent case-control literature
indicates the opposite.6 Apart from extremely rare pedigrees with
multiple cases of CML/myeloproliferative disorders,7 there is essen-
tially no data on familial aggregation of CML in the population.
According to The National CML Society, “Occasionally, there are
families that may have other members living with leukemia,
however, there is no conclusive evidence that family members
are predisposed to develop leukemia.”8
Taking advantage of high-quality registry data from Sweden,
we conducted a population-based registry study to evaluate risk of
CML, MPN, AML, and other malignancies among 9491 ﬁrst-degree
relatives of 4619 patients (45% females) with CML compared with
42 474 ﬁrst-degree relatives of matched controls. Our methods
have been previously described.3 In brief, using the Swedish Cancer
Registry, we identiﬁed all patients with a primary diagnosis of
CML diagnosed between 1958 and 2004. For each CML patient,
4 population-based controls (matched by sex, year of birth, and
county of residence) were chosen randomly from the Swedish
population database. All control individuals had to be alive at the
time of CML diagnosis for their corresponding case patient and
without a hematologic malignancy at the date of CML diagnosis
for their corresponding case patient. We obtained information on
all ﬁrst-degree relatives of cases and controls from the Swedish
Multigenerational Registry, which includes data on parent-
sibling-offspring relations for all Swedish citizens born in 1932
or later. We used a marginal survival model to calculate familial
aggregation.
We found that neither CML (relative risk, 1.62; 95% conﬁdence
interval, 0.52-5.11), AML (0.94; 0.44-2.0), nor MPN (1.11; 0.58-
2.17) aggregated signiﬁcantly in relatives of patients with CML
(vs relatives of controls) (Table 1). In addition, the relative risks
for any lymphoproliferative, hematologic, or solid tumor were
not signiﬁcantly increased. We also analyzed the risks in relatives
by gender and age at diagnosis of proband (<60 vs .60 years) and
could not reveal any signiﬁcant associations (data not shown).
CML patients may worry about their family members having a
potentially increased risk of developing CML or other cancer. In
this population-based study, including all age groups of patients
with CML, we found no signiﬁcant familial aggregation for CML,
AML, MPN, lymphoproliferative neoplasm, or any other cancer
among relatives of CML patients (vs relatives of matched controls).
Our ﬁndings are in sharp contrast to those observed in MPNs where
an increased familial aggregation supports the notion that genetic
susceptibility genes may play a strong role in these patients.
Magnus Bjo¨rkholm
Department of Medicine,
Karolinska University Hospital and Karolinska Institutet,
Stockholm, Sweden
460 CORRESPONDENCE BLOOD, 18 JULY 2013 x VOLUME 122, NUMBER 3
For personal use only.on June 3, 2016. by guest  www.bloodjournal.orgFrom 
Sigurdur Y. Kristinsson
Department of Medicine,
Karolinska University Hospital and Karolinska Institutet,
Stockholm, Sweden
Department of Hematology, Landspitali National University Hospital,
Faculty of Medicine, University of Iceland,
Reykjavik, Iceland
Ola Landgren
Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research,
National Cancer Institute, National Institutes of Health,
Bethesda, MD
Lynn R. Goldin
Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics,
National Cancer Institute, National Institutes of Health,
Bethesda, MD
Acknowledgments: The authors thank Shiva Ayobi (The National Board of
Health and Welfare, Stockholm, Sweden), Susanne Dahllo¨f (Statistics Sweden,
Orebro, Sweden), and Emily Steplowski (Information Management Services,
Silver Spring, MD) for their efforts in the development of this database.
This work was supported by the Intramural Research Program of the
National Cancer Institute, National Institutes of Health, and by grants from the
Adolf H. Lundin Charitable Foundation, Swedish Cancer Society, and the
regional agreement on medical training and clinical research between
Stockholm County Council and Karolinska Institutet.
Contribution: S.Y.K., O.L., and M.B. collected and assembled the data; M.B.
and L.R.G. wrote the manuscript; and all authors were responsible for the
conception, design, data analysis, interpretation and final approval of the
manuscript.
Conflict-of-interest disclosure: The authors declare no competing financial
interests.
Correspondence: Magnus Bjo¨rkholm, Department of Medicine, Karolinska
University Hospital and Institutet, SE-171 76 Stockholm, Sweden; e-mail:
magnus.bjorkholm@karolinska.se.
References
1. Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative
disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol.
2007;25(35):5630-5635.
2. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J,
Bjo¨rkholm M. Increased risks of polycythemia vera, essential
thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of
11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;
112(6):2199-2204.
3. Goldin LR, Kristinsson SY, Liang XS, Derolf AR, Landgren O, Bjo¨rkholm M.
Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.
J Clin Oncol. 2012;30(2):179-183.
4. Heyssel R, Brill AB, Woodbury LA, et al. Leukemia in Hiroshima atomic bomb
survivors. Blood. 1960;15:313-331.
5. Mehlman MA. Dangerous and cancer-causing properties of products and
chemicals in the oil refining and petrochemical industries. Part XXX: causal
relationship between chronic myelogenous leukemia and benzene-containing
solvents. Ann N Y Acad Sci. 2006;1076:110-119.
6. Lamm SH, Engel A, Joshi KP, Byrd DM 3rd, Chen R. Chronic myelogenous
leukemia and benzene exposure: a systematic review and meta-analysis of the
case-control literature. Chem Biol Interact. 2009;182(2-3):93-97.
7. Lillicrap DA, Sterndale H. Familial chronic myeloid leukaemia. Lancet. 1984;
2(8404):699.
8. The National CML Society. General leukemia questions. Available at: www.
nationalcmlsociety.org/faq/general-leukemia-questions. Accessed May 7, 2013.
To the editor:
A missense mutation in ANKRD26 segregates with thrombocytopenia
Inherited thrombocytopenias form a heterogenous group of diseases
characterized by decreased platelet count and increased risk of
bleeding. Mutations in at least 17 genes have been associated with
autosomal-recessive, autosomal-dominant, and X-linked forms of the
disease (recently reviewed by Balduini and Savoia1). Autosomal-
dominant nonsyndromic thrombocytopenia-2 (THC2; MIM 188000)
is characterized by decreased platelet count, mild propensity to
bleeding, normal platelet function, normal numbers of megakaryo-
cytes, and normal maturation stages, suggesting defective platelet
production or release.2 Morphologically, platelets and megakaryocytes
appear normal under light microscopy, but a recent study suggests the
presence of particulate cytoplasmic structures in ANKRD26 platelets
and megakaryocytes when examined under electron microscopy.3
Genetic studies have identiﬁedmutations of the 59 untranslated region
(UTR) of the ANKRD26 gene as the underlying cause of the
phenotype.4 Since the initial report, additional mutations have
been described in the same 22-nucleotide stretch of the 59 UTR in
a total of 21 pedigrees that are postulated to cause THC2 by
upregulation of ANKRD26 expression.2,4
We carried out a whole-exome sequencing experiment on 2
individuals, an affected father-daughter pair, from a 4-generation
Saudi Arabian family with autosomal-dominant nonsyndromic
thrombocytopenia (Figure 1). The proband, a 4-year-old girl, presented
with a history of bruising. Initial investigations revealed mild
thrombocytopenia and iron deﬁciency anemia requiring only 3 trans-
fusions since birth. Laboratory investigations revealed the following:
hemoglobin, 12.2 g/dL; white blood cells, 11.083 109/L; neutrophil
count, 5.7 3 109/L; platelet count, 26 3 109/L (mean platelet
Table 1. Risk of myeloid, lymphoid, and solid malignancies in
relatives of patients with CML
Outcome in relatives
CML,
n 5 9491
Controls,
n 5 42 474 RR 95% CI
Myeloid
AML 8 38 0.95 0.44-2.0
MDS 0 7 — —
AML/MDS 8 45 0.81 0.38-1.70
CML 4 11 1.62 0.37-7.2
MPN 11 44 1.14 0.59-2.20
Any myeloid malignancy 23 100 1.04 0.64-1.68
Lymphoid
NHL 35 145 1.1 0.75-1.60
HL 3 26 0.52 0.16-1.71
CLL 14 52 1.2 0.69-2.20
WM 0 2 — —
MM 11 52 0.96 0.50-1.85
Any lymphoproliferative malignancy 65 276 1.07 0.80-1.41
ALL 4 9 1.98 0.61-6.40
Any hematologic malignancy 92 383 1.09 0.86-1.37
Any solid tumor 998 4312 1.04 0.97-1.12
Any cancer 1089 4695 1.05 0.98-1.12
ALL, acute lymphoblastic leukemia; CI, confidence interval; CLL, chronic
lymphocytic leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome;
MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RR, risk ratio; WM, Waldenstro¨m
macroglobulinemia; —, not computed.
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